NZ504292A - Methods and compositions for enhancing immune response using a targeted delivery system and for the production of in vitro mabs - Google Patents
Methods and compositions for enhancing immune response using a targeted delivery system and for the production of in vitro mabsInfo
- Publication number
- NZ504292A NZ504292A NZ504292A NZ50429298A NZ504292A NZ 504292 A NZ504292 A NZ 504292A NZ 504292 A NZ504292 A NZ 504292A NZ 50429298 A NZ50429298 A NZ 50429298A NZ 504292 A NZ504292 A NZ 504292A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antigen
- vitro
- immune cells
- csf
- interferon
- Prior art date
Links
- 238000000338 in vitro Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 7
- 108091007433 antigens Proteins 0.000 abstract 7
- 102000036639 antigens Human genes 0.000 abstract 7
- 210000002865 immune cell Anatomy 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- -1 IL- 10 Proteins 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 102100022987 Angiogenin Human genes 0.000 abstract 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 abstract 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 abstract 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 abstract 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 abstract 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 abstract 1
- 102000002227 Interferon Type I Human genes 0.000 abstract 1
- 108010014726 Interferon Type I Proteins 0.000 abstract 1
- 102000008070 Interferon-gamma Human genes 0.000 abstract 1
- 108010074328 Interferon-gamma Proteins 0.000 abstract 1
- 108010002352 Interleukin-1 Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 108010002386 Interleukin-3 Proteins 0.000 abstract 1
- 108090000978 Interleukin-4 Proteins 0.000 abstract 1
- 108010002616 Interleukin-5 Proteins 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 108010002586 Interleukin-7 Proteins 0.000 abstract 1
- 108090001007 Interleukin-8 Proteins 0.000 abstract 1
- 108010002335 Interleukin-9 Proteins 0.000 abstract 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 abstract 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 abstract 1
- 102100037611 Lysophospholipase Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010058864 Phospholipases A2 Proteins 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 108010072788 angiogenin Proteins 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 210000000628 antibody-producing cell Anatomy 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000837 carbohydrate group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 abstract 1
- 231100000655 enterotoxin Toxicity 0.000 abstract 1
- 229940126864 fibroblast growth factor Drugs 0.000 abstract 1
- 102000034356 gene-regulatory proteins Human genes 0.000 abstract 1
- 108091006104 gene-regulatory proteins Proteins 0.000 abstract 1
- 210000003714 granulocyte Anatomy 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ceramic Engineering (AREA)
- Transplantation (AREA)
- Genetics & Genomics (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6515597P | 1997-11-10 | 1997-11-10 | |
| US7581198P | 1998-02-24 | 1998-02-24 | |
| US10745598P | 1998-11-06 | 1998-11-06 | |
| PCT/US1998/023957 WO1999024066A2 (en) | 1997-11-10 | 1998-11-10 | Methods and compositions for enhancing immune response and for the production of in vitro mabs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ504292A true NZ504292A (en) | 2003-03-28 |
Family
ID=27370737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ504292A NZ504292A (en) | 1997-11-10 | 1998-11-10 | Methods and compositions for enhancing immune response using a targeted delivery system and for the production of in vitro mabs |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1039933B8 (enExample) |
| JP (3) | JP4588210B2 (enExample) |
| AT (1) | ATE317269T1 (enExample) |
| AU (3) | AU757357B2 (enExample) |
| CA (1) | CA2309602C (enExample) |
| DE (1) | DE69833455T2 (enExample) |
| NZ (1) | NZ504292A (enExample) |
| WO (1) | WO1999024066A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010055581A1 (en) | 1994-03-18 | 2001-12-27 | Lawrence Tamarkin | Composition and method for delivery of biologically-active factors |
| US7229841B2 (en) | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
| US6407218B1 (en) | 1997-11-10 | 2002-06-18 | Cytimmune Sciences, Inc. | Method and compositions for enhancing immune response and for the production of in vitro mabs |
| EP1133994A1 (en) * | 2000-03-11 | 2001-09-19 | Biognostik Gesellschaft für biomolekulare Diagnostik mbH | A method for reversing the immunosuppressive effects of the Melanoma Inhibitory Activity "MIA" |
| JP5175020B2 (ja) * | 2001-04-30 | 2013-04-03 | サイティミューン サイエンシーズ， インコーポレイテッド | コロイド状金属組成物および方法 |
| AU2004311630A1 (en) | 2003-12-02 | 2005-07-21 | Cytimmune Sciences, Inc. | Methods and compositions for the production of monoclonal antibodies |
| US20050175584A1 (en) * | 2004-01-28 | 2005-08-11 | Paciotti Giulio F. | Functionalized colloidal metal compositions and methods |
| KR100836745B1 (ko) * | 2007-01-31 | 2008-06-10 | (주)두비엘 | Ｈｂｖ 백신 및 그의 제조 방법 |
| US8877156B2 (en) | 2007-06-26 | 2014-11-04 | New York University | Contrast agents anchored by thiols on nanoparticles |
| AU2008302035A1 (en) * | 2007-09-21 | 2009-03-26 | Cytimmune Sciences, Inc. | Nanotherapeutic colloidal metal compositions and methods |
| CA2706700A1 (en) | 2007-11-08 | 2009-05-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
| JP5364310B2 (ja) * | 2008-07-14 | 2013-12-11 | アルフレッサファーマ株式会社 | 反応性物質が結合した微小粒子の安定化方法および該微小粒子含有試薬 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57502090A (enExample) * | 1980-07-18 | 1982-11-25 | ||
| CA1214123A (en) * | 1983-01-20 | 1986-11-18 | Masashi Matsui | Cell lines for use in the preparation of hybridoma cells |
| JPS61104796A (ja) * | 1984-10-26 | 1986-05-23 | Chemo Sero Therapeut Res Inst | モノクロ−ナル抗体の製造方法 |
| JPS62162963A (ja) * | 1986-01-10 | 1987-07-18 | Sadao Shiosaka | 金属コロイド粒子を担体とする低分子物質に対する特異抗体の作成法 |
| ATE270111T1 (de) * | 1993-03-18 | 2004-07-15 | Cytimmune Sciences Inc | Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren |
| JPH07227299A (ja) * | 1994-02-14 | 1995-08-29 | Kyoto Daiichi Kagaku:Kk | Ｄｎａの特定塩基配列の検出方法及びその装置 |
| US5686578A (en) * | 1994-08-05 | 1997-11-11 | Immunomedics, Inc. | Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype |
| JPH09107980A (ja) * | 1995-08-17 | 1997-04-28 | Japan Tobacco Inc | 新規生理活性タンパク |
| US6407218B1 (en) * | 1997-11-10 | 2002-06-18 | Cytimmune Sciences, Inc. | Method and compositions for enhancing immune response and for the production of in vitro mabs |
| ATE320270T1 (de) * | 1997-11-10 | 2006-04-15 | Cytimmune Sciences Inc | Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren |
-
1998
- 1998-11-10 AT AT98958518T patent/ATE317269T1/de active
- 1998-11-10 WO PCT/US1998/023957 patent/WO1999024066A2/en not_active Ceased
- 1998-11-10 AU AU14548/99A patent/AU757357B2/en not_active Ceased
- 1998-11-10 EP EP98958518A patent/EP1039933B8/en not_active Expired - Lifetime
- 1998-11-10 NZ NZ504292A patent/NZ504292A/xx not_active IP Right Cessation
- 1998-11-10 JP JP2000520153A patent/JP4588210B2/ja not_active Expired - Fee Related
- 1998-11-10 CA CA2309602A patent/CA2309602C/en not_active Expired - Fee Related
- 1998-11-10 DE DE69833455T patent/DE69833455T2/de not_active Expired - Lifetime
-
2003
- 2003-05-23 AU AU2003204353A patent/AU2003204353B2/en not_active Ceased
-
2006
- 2006-11-10 AU AU2006235956A patent/AU2006235956B2/en not_active Ceased
-
2009
- 2009-06-17 JP JP2009144707A patent/JP2009292818A/ja active Pending
-
2012
- 2012-09-27 JP JP2012214639A patent/JP2013014616A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE69833455D1 (de) | 2006-04-20 |
| WO1999024066A3 (en) | 1999-12-09 |
| AU2006235956B2 (en) | 2010-02-11 |
| EP1039933A2 (en) | 2000-10-04 |
| AU757357B2 (en) | 2003-02-20 |
| WO1999024066A2 (en) | 1999-05-20 |
| DE69833455T2 (de) | 2006-10-19 |
| EP1039933B1 (en) | 2006-02-08 |
| JP2009292818A (ja) | 2009-12-17 |
| ATE317269T1 (de) | 2006-02-15 |
| JP4588210B2 (ja) | 2010-11-24 |
| AU2006235956A1 (en) | 2006-11-30 |
| AU2003204353B2 (en) | 2006-08-10 |
| JP2013014616A (ja) | 2013-01-24 |
| CA2309602A1 (en) | 1999-05-20 |
| JP2002503639A (ja) | 2002-02-05 |
| AU1454899A (en) | 1999-05-31 |
| CA2309602C (en) | 2011-04-26 |
| EP1039933B8 (en) | 2006-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Noelle et al. | Cognate interactions between helper T cells and B cells. V. Reconstitution of T helper cell function using purified plasma membranes from activated Th1 and Th2 T helper cells and lymphokines. | |
| NZ504292A (en) | Methods and compositions for enhancing immune response using a targeted delivery system and for the production of in vitro mabs | |
| US6407218B1 (en) | Method and compositions for enhancing immune response and for the production of in vitro mabs | |
| Adel-Patient et al. | Genetic immunisation with bovine β-lactoglobulin cDNA induces a preventive and persistent inhibition of specific anti-BLG IgE response in mice | |
| JP2002503639A5 (enExample) | ||
| JP2001522818A5 (enExample) | ||
| CA2309604A1 (en) | Compositions and methods for targeted delivery of factors | |
| Okano et al. | Interleukin‐4‐independent production of Th2 cytokines by nasal lymphocytes and nasal eosinophilia in murine allergic rhinitis | |
| Jabara et al. | Engagement of CD14 on monocytes inhibits the synthesis of human Igs, including IgE. | |
| Müller et al. | Differential production of macrophage inflammatory protein 1γ (MIP-1γ), lymphotactin, and MIP-2 by CD4+ Th subsets polarized in vitro and in vivo | |
| Evans et al. | Synergistic interaction of bacterial lipopolysaccharide and the monocyte‐macrophage colony‐stimulating factor: potential quantitative and qualitative changes in macrophage‐produced cytokine bioactivity | |
| WO1998037912A1 (fr) | Nouveau vaccin composite contenant un antigene, un anticorps et un adn recombinant et son procede de preparation | |
| Livnat et al. | Recruitment of effector lymphocytes by initiator lymphocytes: role of a trypsin‐sensitive membrane component | |
| Hashiguchi et al. | Naïve CD4+ T cells of Peyer's patches produce more IL-6 than those of spleen in response to antigenic stimulation | |
| Ali et al. | Effect of interleukins on antibody production by Epstein-Barr virus transformed B cells | |
| Lee et al. | A DNA adjuvant encoding a fusion protein between anti‐CD3 single‐chain Fv and AIMP1 enhances T helper type 1 cell‐mediated immune responses in antigen‐sensitized mice | |
| Singh et al. | Granulocyte chemotactic protein-2 mediates adaptive immunity in part through IL-8Rβ interactions | |
| Bright et al. | Examination of lymphokines induced in mice following immunization with recombinant simian virus 40 large tumor antigen | |
| Hannya et al. | The 1st step initiation essential for allergen‐specific IgE antibody production upon the 2nd step: Induction of non‐specific IgE+ small B cells containing secondly‐sensitized allergen‐specific ones in mice firstly‐sensitized with an allergen | |
| Liu et al. | A Prophylactic Effect of an Oligodeoxynucleotide Containing a Cytidine–Guanosine Motif against Japanese Cedar Pollen-Induced T-Helper Type 2 Allergic Response | |
| EP1933850A2 (en) | Aptamers as agonists | |
| AU1090895A (en) | Cytokines from natural killer or t cells | |
| Abrahamsson | Immunosuppression in childhood malignancy: Aspects on humoral immunity and serum cytokine levels. | |
| Mohamed | STUDIES OF IMMUNITY TO PASTEURELLA MULTOCIDA (PASTEURELLOSIS, RESPIRATORY DISEASES) | |
| RU2021115314A (ru) | Способы и материалы для лечения рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |